Until recently, oncologists had to comb through mountains of raw data of cancer patients to draw any meaningful information, but now Tempus has come to change that. Lack of standardized data has been one of the biggest impediments to effective cancer treatments. Most of the genomic and therapeutic information on people who are battling with various forms of cancer exists in the form of doctors’ notes. This reality lives doctors with very little information to act upon whenever they are prescribing treatment to their patients.
Entrepreneur Eric Lefskofsky has partnered with other players in the field of medicine to champion the next frontier in cancer treatment which is data-driven precision medicine. Through a joint venture called Tempus, the seasoned businessman is expected to revolutionize healthcare as far autoimmune diseases such as cancer are concerned and read full article.
It never dawned on Eric Lefkofsky that he could find his calling in the field of medicine. Eric had always been an investor in the area of technology and had developed several disruptive brands in this sector. In 2015, Eric Lefkofsky changed his course in business and decided to venture into medical research when someone close to him needed cancer treatment. It was at this moment of horror and pain that Eric made a life-changing discovery. Eric noticed that oncologists were working with limited data. Most of the information that existed was in forms which they couldn’t draw any meaningful analyses from it.
Eric decided to co-found a company that could speed up research in the medical field of oncology. Eric wanted to put effective therapies in the hands of cancer patients as soon as he could. Through Tempus, Eric’s dream is beginning to take shape one step after the other. Already, the company has begun analyzing medical records from over 1,000 breast cancer patients with the aim of drawing analytics that can help scientists come up with data-driven precision medicine and what Eric knows.
When a doctor is handling various cancer patients, they can compare the patient’s clinical and genomic data against that of other patients who are living with the same type of cancer. With various cases of cancer under one pool, doctors can be able to know what works and what doesn’t.
Apart from making a lot of progress in the field of entrepreneurship, Eric Lefkofsky is also a seasoned humanitarian. He is involved with initiatives that aim at making the world a better place for everyone and Eric’s lacrosse camp.
Seattle Genetics is ranked among the most prestigious biotech companies in the United States and aims at further developing its operations is in the coming years. The firm has been playing a significant role of packaging and conducting studies on the various antibodies as well as their roles. Seattle Genetics has highly invested in doing researches concerning the human antibodies with the aim of discovering the most effective bone in attacking and thoroughly destroying cancer cells. The company has a great team of employees who are highly committed to delivering the best, and this has profoundly contributed to the high growth of the firm over the past years.
The firm has great strategies that enable it to stand out among many other companies in the market, and its unique antibody that delivers payloads of toxins to cancer cells has allowed the firm gain more prestige. Many individuals in Seattle hope that the company will keep growing in the coming years to become a prolific pharmaceutical company that they have been highly looking toward for a long time. Besides, they hope that the company will retain its current location in Seattle and that it will not reconsider relocating to another place regardless of its success. The people in Seattle are highly hopeful on the provision of better services for the firm and are willing to give their best concerning the research on the cancer antibody.
In addition to that, the company has over nine hundred employees and hopes to employ more in the coming years. It is also proud of its immense amount of net worth which has proved it to be one of the most prolific firms in the United States. Besides, Seattle Genetics is highly ambitious towards evolving from a biotech company into a massive pharmaceutical enterprise in the coming years. Its high reliance on research and marketing will see it hire more employees in the coming year.
Clay Siegal is one of the significant contributors to the success of the firm and is profoundly ambitious towards growing the company to a bigger and successful one. Clay is not willing to sell his form to other bigger pharmaceutical firms as he believes that its one major way of encouraging failure.
In addition to that, Clay has a lot of experience in the pharmaceutical field, and since appointment in the firm, he has shared his amendable skills with his team of employees which has, in turn, enhanced their performance. Besides, Clay has helped the company enter into partnerships with various pharmaceutical firms majoring in oncology which has helped it acquire ideas for more development.